研究業績(原著論文のみ)/ Publications(Original Articles only)

2023年度

Downregulated expression of PBRM1 in sarcomatoid hepatocellular carcinoma
Yoshida T, Sakai K, Kaibori M, Ishida M, Tanaka S, Kubo S, Nakai T, De Velasco MA, Matsushima H, Tsuta K, Sekimoto M, Nishio K.
Oncol Lett . 2024 Jan 26;27(3):124. doi: 10.3892/ol.2024.14257. eCollection 2024 Mar.

Copy Number Gain in Androgen Receptors Predicts the Poor Prognosis in Japanese Castration-resistant Prostate Cancer.
Sakamoto S, Ando K, Pae S, Zhao X, Sakai K, Sato K, Saito S, Yamada Y, Rii J, Goto Y, Sazuka T, Imamura Y, Anzai N, Akakura K, Nishio K, Ichikawa T.
nticancer Res . 2024 Feb;44(2):639-647. doi: 10.21873/anticanres.16853.

Bisabosqual A: A novel asparagine synthetase inhibitor suppressing the proliferation and migration of human non-small cell lung cancer A549 cells.
Pan Y, Suzuki T, Sakai K, Hirano Y, Ikeda H, Hattori A, Dohmae N, Nishio K, Kakeya H.
Eur J Pharmacol . 2023 Dec 5:960:176156. doi: 10.1016/j.ejphar.2023.176156. Epub 2023 Oct 30.

Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy.
Tanizaki J, Kuroda H, Yokoyama T, Takahama M, Shoda H, Nakamura A, Kitamura Y, Mamesaya N, Kadota Y, Sawa K, Okishio K, Okada M, Suminaka C, Noda K, Sakai K, Chiba Y, Nishio K, Chamoto K, Honjo T, Yamamoto N, Nakagawa K, Hayashi H.
JTO Clin Res Rep . 2023 Oct 13;4(12):100590. doi: 10.1016/j.jtocrr.2023.100590. eCollection 2023 Dec.

NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study.
Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi K, Ikeda N, Tanahashi M, Tambo Y, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, Okamoto T, Yanagitani N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K.
Mol Oncol . 2024 Feb;18(2):305-316. doi: 10.1002/1878-0261.13542. Epub 2023 Oct 28.

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
Nishio K, Sakai K, Nishio M, Seto T, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa K. Transl Lung Cancer Res . 2023 Aug 30;12(8):1702-1716. doi: 10.21037/tlcr-22-736. Epub 2023 Aug 10.

Low frequency of intracranial progression in advanced NSCLC patients treated with cancer immunotherapies.
Kemmotsu N, Ninomiya K, Kunimasa K, Ishino T, Nagasaki J, Otani Y, Michiue H, Ichihara E, Ohashi K, Inoue T, Tamiya M, Sakai K, Ueda Y, Dansako H, Nishio K, Kiura K, Date I, Togashi Y.
Int J Cancer . 2024 Jan 1;154(1):169-179. doi: 10.1002/ijc.34700. Epub 2023 Aug 23.

Impact of Smad4 and p53 mutations on the prognosis of patients with pancreatic ductal adenocarcinoma undergoing chemotherapy.
Kamata K, Takenaka M, Nishida N, Hara A, Otsuka Y, Tanaka H, Omoto S, Minaga K, Yamao K, Chiba Y, Sakai K, Nishio K, Watanabe T, Kudo M.
Int J Clin Oncol.2023 Aug 18. doi: 10.1007/s10147-023-02396-w. Online ahead of print.

Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain.
Fujita Y, Matsuoka H, Chiba Y, Tsurutani J, Yoshida T, Sakai K, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takeda M, Okuno T, Takegawa N, Haratani K, Takahama T, Tanizaki J, Koyama A, Nishio K, Nakagawa K.
Oncol Lett.2023 Jul 4;26(2):355. doi: 10.3892/ol.2023.13941. eCollection 2023 Aug.

Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR+non-small-cell lung cancer.
Nishio M, Atagi S, Goto K, Hosomi Y, Seto T, Hida T, Nakagawa K, Yoshioka H, Nogami N, Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N, Nishio K.
Transl Lung Cancer Res.2023 Jun 30;12(6):1167-1184. doi: 10.21037/tlcr-22-632. Epub 2023 Jun 13.

Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Garon EB, Reck M, Nishio K, Heymach JV, Nishio M, Novello S, Paz-Ares L, Popat S, Aix SP, Graham H, Butts BD, Visseren-Grul C, Nakagawa K; RELAY study investigators.
ESMO Open.2023 Aug;8(4):101580. doi: 10.1016/j.esmoop.2023.101580. Epub 2023 Jun 28.

Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H.
J Thorac Oncol.2023 Jun 25;S1556-0864(23)00633-0. doi: 10.1016/j.jtho.2023.06.012. Online ahead of print.

Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial.
Yonesaka K, Hayashi H, Nakamura A, Sato Y, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Ito K, Yano Y, Matsumoto H, Daga H, Hata A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Nakagawa K.
Clin Lung Cancer.2023 Sep;24(6):519-527.e4. doi: 10.1016/j.cllc.2023.05.008. Epub 2023 Jun 3.

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
Takakura T, Kanemura H, Sakai K, Nishio K, Nakagawa K, Hayashi H.
JTO Clin Res Rep.2023 May 4;4(6):100523. doi: 10.1016/j.jtocrr.2023.100523. eCollection 2023 Jun.

Performance of Ultra-Rapid Idylla™ EGFR Mutation Test in Non-Small-Cell Lung Cancer and Its Potential at Clinical Molecular Screening
Suda K, Sakai K, Ohira T, Chikugo T, Satou T, Matsubayashi J, Nagao T, Ikeda N, Tsutani Y, Mitsudomi T, Nishio K.
Cancers (Basel). 2023 May 7;15(9):2648. doi: 10.3390/cancers15092648.

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial.
Izawa N, Masuishi T, Takahashi N, Shoji H, Yamamoto Y, Matsumoto T, Sugiyama K, Kajiwara T, Kawakami K, Aomatsu N, Kondoh C, Kawakami H, Takegawa N, Esaki T, Shimokawa M, Nishio K, Narita Y, Hara H, Sunakawa Y, Boku N, Moriwaki T, Eguchi Nakajima T, Muro K.
Target Oncol. 2023 May;18(3):369-381. doi: 10.1007/s11523-023-00963-9. Epub 2023 May 6.

Uterine angioleiomyoma with disseminated intravascular coagulation: a case report.
Sato H, Murakami K, Fujishima R, Otani T, Sakai K, Nishio K, Matsumura N.
BMC Womens Health. 2023 Apr 3;23(1):157. doi: 10.1186/s12905-023-02292-5.

Activation of ERK1/2 by MOS and TPL2 leads to dasatinib resistance in chronic myeloid leukemia cells
Tsubaki M, Takeda T, Koumoto Y, Usami T, Matsuda T, Seki S, Sakai K, Nishio K, Nishida S.
Cell Prolif. 2023 Feb 27;e13420. doi: 10.1111/cpr.13420. Online ahead of print.

Genetic variants of cancer‑associated genes analyzed using next‑generation sequencing in small sporadic vestibular schwannomas
Fujita T, Sakai K, Uehara N, Hoshi Y, Mori A, Koyama H, Sato M, Saito K, Osaki Y, Nishio K, Doi K.
Oncol Lett. 2023 Feb 8;25(3):121. doi: 10.3892/ol.2023.13707. eCollection 2023 Mar.

Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan
Takahashi T, Nishio M, Nishino K, Yoshiki Y, Shiraiwa N, Emir B, Iadeluca L, Yatabe Y, Nishio K.
Cancer Sci. 2023 Feb 8. doi: 10.1111/cas.15752. Online ahead of print.

Morphine versus oxycodone for cancer pain using a catechol-O-methyltransferase genotype biomarker
Matsuoka H, Tsurutani J, Chiba Y, Fujita Y, Sakai K, Yoshida T, Nakura M, Sakamoto R, Makimura C, Ohtake Y, Tanaka K, Hayashi H, Takeda M, Okuno T, Takegawa N, Haratani K, Koyama A, Nishio K, Nakagawa K.
Oncologist. 2023 Mar 17;28(3):278-e166. doi: 10.1093/oncolo/oyac233.

2022年度

Cytoplasmic p53 aggregates accumulated in p53-mutated cancer correlate with poor prognosis
Iwahashi N, Ikezaki M, Komohara Y, Fujiwara Y, Noguchi T, Nishioka K, Sakai K, Nishio K, Ueda M, Ihara Y, Uchimura K, Ino K, Nishitsuji K.
PNAS Nexus. 2022 Jul 25;1(3):pgac128. doi: 10.1093/pnasnexus/pgac128. eCollection 2022 Jul.

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
Watanabe S, Sakai K, Matsumoto N, Koshio J, Ishida A, Abe T, Ishikawa D, Tanaka T, Aoki A, Kajiwara T, Koyama K, Miura S, Goto Y, Sekiya T, Suzuki R, Kushiro K, Fujisaki T, Yanagimura N, Ohtsubo A, Shoji S, Nozaki K, Saida Y, Yoshizawa H, Nishio K, Kikuchi T.
Cancers (Basel). 2022 Dec 29;15(1):204. doi: 10.3390/cancers15010204.

Combination bezafibrate and nivolumab treatment of patients with advanced non-small cell lung cancer
Tanaka K, Chamoto K, Saeki S, Hatae R, Ikematsu Y, Sakai K, Ando N, Sonomura K, Kojima S, Taketsuna M, Kim YH, Yoshida H, Ozasa H, Sakamori Y, Hirano T, Matsuda F, Hirai T, Nishio K, Sakagami T, Fukushima M, Nakanishi Y, Honjo T, Okamoto I.
Sci Transl Med. 2022 Dec 14;14(675):eabq0021. doi: 10.1126/scitranslmed.abq0021. Epub 2022 Dec 14.

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX
Okamoto W, Sakai K, Makiyama A, Yamamoto Y, Shitara K, Denda T, Izawa N, Nakano Y, Nishina T, Esaki T, Hara H, MiuraY, Boku N, Yamazaki K, Hironaka S, Misumi T ,Hyodo I, Muro K, Nishio K.
ESMO Open. 2022 Dec;7(6):100592. doi: 10.1016/j.esmoop.2022.100592. Epub 2022 Dec 8.

Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K, Haratani K, Tsujikawa T, Makutani Y, Kawakami H, Takeda M, Yonesaka K, Tanaka K, Iwasa T, Hayashi H, Ito A, Nishio K, Nakagawa K.
Lung Cancer. 2022 Dec;174:71-82. doi: 10.1016/j.lungcan.2022.10.012. Epub 2022 Oct 30.

Targeted-sequence of normal urothelium and tumor of patients with non-muscle invasive bladder cancer.
Hayashi Y, Fujita K, Sakai K, Adomi S, Banno E, Nojima S, Tomiyama E, Matsushita M, Kato T, Hatano K, Kawashima A, Minami T, Morii E, Uemura H, Nishio K, Nonomura N.
Sci Rep. 2022 Oct 5;12(1):16642. doi: 10.1038/s41598-022-21158-8.

The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC
Kanemura H, Hayashi H, Tomida S, Tanizaki J, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K.
JTO Clin Res Rep. 2022 Jul 1;3(8):100373. doi: 10.1016/j.jtocrr.2022.100373. eCollection 2022 Aug.

Recommendations related to the analytical equivalence assessment of gene panel testing
Nagai S, Nishihara H, Suzuki T, Nishio K, Taniguchi H, Tsuchihara K, Nakamura K, Takamatsu R, Ueno T, Aburatani H, Kohno T, Kohsaka S.
Cancer Sci. 2022 Oct;113(10):3282-3290. doi: 10.1111/cas.15513. Epub 2022 Aug 19.

Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L)
Hayashi H, Yonesaka K, Nakamura A, Fujimoto D, Azuma K, Sakata S, Tachihara M, Ikeda S, Yokoyama T, Hataji O, Yano Y, Hirano K, Daga H, Okada H, Chiba Y, Sakai K, Nishio K, Yamamoto N, Nakagawa K.
Lung Cancer. 2022 Jun;168:38-45. doi: 10.1016/j.lungcan.2022.04.004. Epub 2022 Apr 12.

Performance of Idylla™ RAS-BRAF mutation test for formalin-fixed paraffin-embedded tissues of colorectal cancer
Makutani Y, Sakai K, Yamada M, Wada T, Chikugo T, Satou T, Iwasa Y, Yamamoto H, de Velasco MA, Nishio K, Kawamura J.
Int J Clin Oncol. 2022 Jul;27(7):1180-1187. doi: 10.1007/s10147-022-02167-z. Epub 2022 Apr 26.

RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With EGFR-Mutated Metastatic NSCLC.
Nishio M, Nishio K, Reck M, Garon EB, Imamura F, Kawaguchi T, Yamaguchi H, Ikeda S, Hirano K, Visseren-Grul C, Ceccarelli M, Wijayawardana SR, Zimmermann A, Matsui T, Enatsu S, Nakagawa K.
JTO Clin Res Rep. 2022 Feb 26;3(4):100303. doi: 10.1016/j.jtocrr.2022.100303. eCollection 2022 Apr.

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
Nozaki K, Watanabe S, Nishio K, Sakai K, Kikuchi T.
Transl Cancer Res. 2022 Jan;11(1):295-298. doi: 10.21037/tcr-21-1850.

ACAGT-007a, an ERK MAPK Signaling Modulator, in Combination with AKT Signaling Inhibition Induces Apoptosis in KRAS Mutant Pancreatic Cancer T3M4 and MIA-Pa-Ca-2 Cells
Khandakar GI, Satoh R, Takasaki T, Fujitani K, Tanabe G, Sakai K, Nishio K, Sugiura R.
Cells. 2022 Feb 17;11(4):702. doi: 10.3390/cells11040702.

Precision cancer genome testing needs proficiency testing involving all stakeholders
Maekawa M, Taniguchi T, Nishio K, Sakai K, Matsushita K, Nakatani K, Ishige T, Ikejiri M, Nishihara H, Sunami K, Yatabe Y, Hatanaka KC, Hatanaka Y, Yamamoto Y, Fukuyama K, Oda S, Saito K, Yokomura M, Kubo Y, Sato H, Tanaka Y, Fuchioka M, Yamasaki T, Matsuda K, Kurachi K, Funai K, Baba S, Iwaizumi M.
Sci Rep. 2022 Jan 27;12(1):1494. doi: 10.1038/s41598-022-05589-x.

Patients with polyclonal hepatocellular carcinoma are at a high risk of early recurrence and have a poor recurrence-free survival period
Kaibori M, Sakai K, Matsushima H, Kosaka H, Matsui K, De Velasco MA, Sekimoto M, Nishio K.
Hepatol Int. 2022 Feb;16(1):135-147. doi: 10.1007/s12072-021-10278-4. Epub 2022 Jan 1.

HER3 augmentation via blockade of EGFR/AKT signaling enhances anticancer activity of HER3-targeting patritumab deruxtecan in EGFR-mutated non-small-cell lung cancer
Yonesaka K, Tanizaki J, Maenishi O, Haratani K, Kawakami H, Tanaka K, Hayashi H, Sakai K, Chiba Y, Tsuya A, Goto H, Otsuka E, Okida H, Kobayashi M, Yoshimoto R, Funabashi M, Hashimoto Y, Hirotani K, Kagari T, Nishio K, Nakagawa K
Clin Cancer Res. 2022 Jan 15;28(2):390-403. doi: 10.1158/1078-0432.CCR-21-3359. Epub 2021 Dec 17.

A Randomized Phase II Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L)
Hayashi H, Sugawara S, Fukuda Y, Fujimoto D, Miura S, Ota K, Ozawa Y, Hara S, Tanizaki J, Azuma K, Omori S, Tachihara M, Nishino K, Bessho A, Chiba Y, Haratani K, Sakai K, Nishio K, Yamamoto N, Nakagawa K
Clin Cancer Res. 2022 Mar 1;28(5):893-902. doi: 10.1158/1078-0432.CCR-21-3194.

Open-label phase II study of the efficacy of nivolumab for cancer of unknown primary
Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, Miura Y, Segawa Y, Takahashi S, Iwamoto Y, Kidera Y, Fukuoka K, Ito A, Chiba Y, Sakai K, Nishio K, Nakagawa K, Hayashi H.
Ann Oncol. 2022 Feb;33(2):216-226. doi: 10.1016/j.annonc.2021.11.009. Epub 2021 Nov 26.

Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma
Rai S, Inoue H, Sakai K, Hanamoto H, Matsuda M, Maeda Y, Haeno T, Watatani Y, Kumode T, Serizawa K, Taniguchi Y, Hirase C, Espinoza JL, Morita Y, Tanaka H, Ashida T, Tatsumi Y, Nishio K, Matsumura I.
Cancer Sci. 2022 Feb;113(2):660-673. doi: 10.1111/cas.15224. Epub 2021 Dec 5.

Predictive value of EGFR mutation in NSCLC patients treated with platinum doublet postoperative chemotherapy
Takahashi T, Sakai K, Kenmotsu H, Yoh K, Daga H, Ohira T, Ueno T, Aoki T, Hayashi H, Yamazaki K, Hosomi Y, Chen-Yoshikawa TF, Okumura N, Takiguchi Y, Sekine A, Haruki T, Yamamoto H, Sato Y, Akamatsu H, Seto T, Saeki S, Sugio K, Nishio M, Inokawa H, Yamamoto N, Nishio K, Tsuboi M.
Cancer Sci. 2022 Jan;113(1):287-296. doi: 10.1111/cas.15171. Epub 2021 Nov 7.

Integrative analysis of gut microbes and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis
Sakurai T, De Velasco MA, Sakai K, Nagai T, Nishiyama H, Hashimoto K, Uemura H, Kawakami H, Nakagawa K, Ogata H, Nishio K, Kudo M.
Mol Oncol. 2022 Apr;16(7):1493-1507. doi: 10.1002/1878-0261.13062. Epub 2021 Jul 28.